![Congress_audience_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-stock/congress_audience_02/9864595-1-eng-GB/congress_audience_02_i770.jpg)
Poziotinib does not meet the expectations to target insertion mutations in HER2 exon 20 in NSCLC
The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor